Project A04

Novel therapeutic approaches for congenital adrenal hyperplasia

Here is supposed to be a picture of Nicole Reisch and Angela Hübner, project A04, CRC/TRR 205.

Univ.-Prof. Dr. Nicole Reisch
nicole.reisch(at)med.uni-muenchen.de
Medizinische Klinik und Poliklinik IV
Endokrinologie, Diabetologie
Klinikum der Universität München

Prof. Dr. Angela Hübner
angela.huebner(at)uniklinikum-dresden.de
Kinder- und Jugendmedizin
Abt. Neuropädiatrie Dresden
Universitätsklinikum Carl Gustav Carus Dresden

Scientific staff

PD Dr.Katrin Köhler  – Postdoc
Tina Schubert – PhD-Student
Nicolas Meese – PhD-Student

Project Description

Project A04 deals with Congenital adrenal hyperplasia (CAH) as it presents one of the most common autosomal recessive disorders. It is caused by steroid 21- hydroxylase deficiency which leads to a complex imbalance of adrenal steroids. Current therapeutic situation is unsatisfactory because it cannot mimic the physiological hormone secretion leading to increased comorbidities and mortality. That is why the project aims to develop new treatments focusing on the therapeutic effect of ACTH antagonists, blocking antibodies and pharmacological chaperones, thus preventing overstimulation and hyperplasia of the adrenal gland.

Aims

(I) Test and advance selective competitive antagonist-peptides and antibodies of the melanocortin 2 receptor (MC2R).
(II) Investigate protein misfolding due to steroid 21-hydroxylase (CYP21A2) mutations and study of CYP21A2 binding molecules as pharmacological treatment options for congenital adrenal hyperplasia (CAH).
(III) Establish, characterise and implement a novel 21-hydroxylase-knock-in mouse model for CAH.

PhD/MD-Thesis

Tina Schubert: Novel therapeutic approaches for congenital adrenal hyperplasia (2017-2020)

Nicolas Meese: Novel Therapeutic Approaches for Congenital Adrenal Hyperplasia – Reconstitution of Cytochrome P450 21A2 Active by Chaperones (2017-2020)